Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients [Phase 2]
A Phase 2 clinical trial comparing MB-CART2019.1 CAR-T therapy to standard of care in patients with Diffuse Large B-cell Lymphoma to assess …
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Compassionate Use (CU) Program of Odronextamab
Compassionate-use program update for odronextamab in relapsed or refractory B-cell lymphomas, including follicular lymphoma and diffuse larg…
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]
A Phase 3 trial evaluating polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin versus rituximab, gemcitabine and …
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]
Genmab's GEN3014 trial in relapsed or refractory hematologic malignancies (relapsed/refractory multiple myeloma, diffuse large B cell lympho…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating Rocbrutinib in participants with relapsed or refractory Non-GCB diffuse large B-cell lymphoma and is …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-11Clinical Trial Update: Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
This clinical trial update describes a nonconforming expanded access protocol for lisocabtagene maraleucel (CAR-T therapy) and notes that it…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL [Phase 2]
Phase 2 trial comparing Pola-RCHP-X to Pola-RCHP in previously untreated diffuse large B-cell lymphoma to assess efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS trial_result · 2025-12-01Clinical Trial Update: A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma [Phase 1]
The document reports a Phase 1 study of glofitamab in combination with rituximab plus Ifosfamide, Carboplatin, and Etoposide Phosphate in re…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma [Phase 2]
This update notes the completion of a Phase 2 trial evaluating first-line R-CHOP in combination with lenalidomide for diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT [Phase 2]
Phase 2 trial evaluating sequential CD19/CD22 CAR-T cell therapy after autologous stem cell transplant in Diffuse large B-cell lymphoma; the…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
This clinical trial update reports on a completed study evaluating the potential cardiotoxic effects of anthracycline chemotherapy in patien…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant [Phase 1]
Phase 1 study evaluating olaparib in combination with high-dose chemotherapy for relapsed or refractory lymphomas undergoing stem cell trans…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study [Phase 1, Phase 2]
This document reports the completion of a long-term safety study of tazemetostat in adults who previously received the drug in earlier trial…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy [Phase 1]
Phase 1 clinical trial evaluating NT-I7 after CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma has completed. The tri…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1]
Regeneron's bbT369 Phase 1 study in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a form of B-cell non-Hodgkin's lymphoma, h…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies [EARLY_Phase 1]
The document summarizes a Phase 1 trial of dose-adjusted EPOCH-R for mature B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Po…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of acalabrutinib with anti-CD19 CAR T-cell therapy for various B-cell lymphomas, in…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] [Phase 2]
A Phase 2 master protocol evaluating SAR-444245 for relapsed or refractory B-cell lymphoma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant [Phase 1]
Phase 1 trial evaluating Purinostat Mesylate for Injection in relapsed or refractory B cell–related tumors, including diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 study update for IKS03 in advanced B-cell non-Hodgkin lymphomas is currently recruiting across multiple subtypes including diffuse l…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of rituximab, chemotherapy, and yttrium-90 ibritumomab tiuxetan in patients with newly diagnosed …